Advances in risk assessment shift the calculus of early intervention trials for MASLD

Advances in risk assessment shift the calculus of early intervention trials for MASLD is a pharma and life sciences industry update from PharmaVoice. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Jolanta M. Wichary, MD, Vice President, Therapeutic Area Lead, Gastroenterology and Hepatology and Jack Martin, MD, FACC, Senior Director, Cardiovascular Therapeutics, Drug Development Solutions, ICON · 2026-08-31

How risk prediction is making early intervention trials in MASLD more feasible.

Source: PharmaVoice